Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain

[1]  C. Sanfeliu,et al.  Astrocytes aged in vitro show a decreased neuroprotective capacity , 2007, Journal of neurochemistry.

[2]  B. Bogerts,et al.  Evidence for a wide extra-astrocytic distribution of S100B in human brain , 2007, BMC Neuroscience.

[3]  J. Rothstein,et al.  Mechanisms of Disease: astrocytes in neurodegenerative disease , 2006, Nature Clinical Practice Neurology.

[4]  Carol Brayne,et al.  Cohort profile: the Medical Research Council Cognitive Function and Ageing Study (CFAS). , 2006, International journal of epidemiology.

[5]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[6]  Xiongwei Zhu,et al.  Involvement of Oxidative Stress in Alzheimer Disease , 2006, Journal of neuropathology and experimental neurology.

[7]  J. O'Brien,et al.  White Matter Lesions in an Unselected Cohort of the Elderly: Molecular Pathology Suggests Origin From Chronic Hypoperfusion Injury , 2006, Stroke.

[8]  G. Perry,et al.  Oxidative Damage to RNA in Neurodegenerative Diseases , 2006, Journal of biomedicine & biotechnology.

[9]  Robert H. Brown,et al.  Caspase-3 Cleaves and Inactivates the Glutamate Transporter EAAT2* , 2006, Journal of Biological Chemistry.

[10]  R. Armstrong.  Laminar Distribution of β-Amyloid Deposits in Dementia With Lewy Bodies and in Alzheimer’s Disease , 2006 .

[11]  T. Klockgether,et al.  Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms , 2006, International Journal of Developmental Neuroscience.

[12]  D. Yew,et al.  Age related changes of various markers of astrocytes in senescence-accelerated mice hippocampus , 2005, Neurochemistry International.

[13]  P. Colditz,et al.  Glial glutamate transporter expression patterns in brains from multiple mammalian species , 2005, Glia.

[14]  R. Mrak,et al.  Glia and their cytokines in progression of neurodegeneration , 2005, Neurobiology of Aging.

[15]  W. Markesbery,et al.  Associations of cortical astrogliosis with cognitive performance and dementia status. , 2005, Journal of Alzheimer's disease : JAD.

[16]  S. Roßner,et al.  Alzheimer's disease β‐secretase BACE1 is not a neuron‐specific enzyme , 2005 .

[17]  H. Bidmon,et al.  Influence of post-mortem delay and storage temperature on the immunohistochemical detection of antigens in the CNS of mice. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[18]  Paul G. Ince,et al.  Vascular pathologies and cognition in a population-based cohort of elderly people , 2004, Journal of the Neurological Sciences.

[19]  J. Wegiel,et al.  Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease , 2004, Neurobiology of Aging.

[20]  P. Dodd,et al.  Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer disease , 2003, Journal of Neural Transmission.

[21]  M. D'Andrea,et al.  Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains , 2003, Brain Research.

[22]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-β in vitro and in situ , 2003, Nature Medicine.

[23]  C. Kawas,et al.  Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease , 2003, Neurobiology of Aging.

[24]  Nick C Fox,et al.  Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease , 2003, Neuroscience Letters.

[25]  A. Fagan,et al.  Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease , 2002, Neurobiology of Disease.

[26]  R. Mrak,et al.  The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease , 2001, Neurobiology of Aging.

[27]  P. Baron,et al.  Glial activation in Alzheimer’s disease: the role of Aβ and its associated proteins , 2001, Neurobiology of Aging.

[28]  R. Mrak,et al.  Interleukin-1, neuroinflammation, and Alzheimer’s disease , 2001, Neurobiology of Aging.

[29]  E. Peskind,et al.  Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease , 2001, Neurochemistry International.

[30]  R. Fukuyama,et al.  The Cerebrospinal Fluid Level of Glial Fibrillary Acidic Protein Is Increased in Cerebrospinal Fluid from Alzheimer’s Disease Patients and Correlates with Severity of Dementia , 2001, European Neurology.

[31]  P. Lantos,et al.  The Neuropathology of Schizophrenia. Progress and Interpretation , 2001 .

[32]  F. Mora,et al.  Glutamatergic neurotransmission in aging: a critical perspective , 2001, Mechanisms of Ageing and Development.

[33]  Ian G. McKeith,et al.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.

[34]  M. Laakso,et al.  Astrogliosis and the ApoE Genotype , 1999, Dementia and Geriatric Cognitive Disorders.

[35]  F. Schmitt,et al.  Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.

[36]  D. Graham,et al.  Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease , 1999, Journal of neuroscience research.

[37]  J. Unger.  Glial reaction in aging and Alzheimer's disease , 1998, Microscopy research and technique.

[38]  M. Rossor,et al.  Increased S100β in the cerebrospinal fluid of patients with frontotemporal dementia , 1997, Neuroscience Letters.

[39]  E. Masliah,et al.  Glutamate Transporter Alterations in Alzheimer Disease Are Possibly Associated with Abnormal APP Expression , 1997, Journal of neuropathology and experimental neurology.

[40]  E. Masliah,et al.  Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease , 1996 .

[41]  K. Blennow,et al.  Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. , 1996, Dementia.

[42]  R. Mrak,et al.  Human brain S100β and S100β mRNA expression increases with age: Pathogenic implications for Alzheimer's disease , 1996, Neurobiology of Aging.

[43]  R. Mrak,et al.  Correlation of Astrocytic S100β Expression with Dystrophic Neurites in Amyloid Plaques of Alzheimer's Disease , 1996, Journal of neuropathology and experimental neurology.

[44]  Paul J. Harrison,et al.  The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins , 1995, Neuroscience Letters.

[45]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[46]  M. Kavanaugh,et al.  Kinetics of a human glutamate transporter , 1995, Neuron.

[47]  W. Griffin,et al.  S100β protein expression in Alzheimer disease: Potential role in the pathogenesis of neuritic plaques , 1994 .

[48]  C. Duyckaerts,et al.  Alterations of glial fibrillary acidic protein mRNA level in the aging brain and in senile dementia of the Alzheimer type , 1993, Neuroscience Letters.

[49]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[50]  R. Oppenheim,et al.  S100 is present in developing chicken neurons and Schwann cells and promotes motor neuron survival in vivo. , 1992, Journal of neurobiology.

[51]  D. Marshak,et al.  Increased S100β neurotrophic activity in Alzheimer's disease temporal lobe , 1992, Neurobiology of Aging.

[52]  S. Barger,et al.  Neurotrophic protein S100 beta stimulates glial cell proliferation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[53]  W. Griffin,et al.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[54]  T. Beach,et al.  Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer's disease visual cortex , 1988, Brain Research.

[55]  L. Wolfson,et al.  Clinico‐pathologic studies in dementia , 1988, Neurology.

[56]  R. Terry,et al.  An immunohistochemical quantification of fibrous astrocytes in the aging human cerebral cortex , 1987, Neurobiology of Aging.

[57]  M. Noppe,et al.  Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome , 1986, Journal of Neurology.

[58]  M. Rapport,et al.  Glial fibrillary acidic protein and Alzheimer‐type senile dementia , 1980, Neurology.

[59]  Paul J. Harrison.  The neuropathology of schizophrenia , 2008 .

[60]  G. Mancardi,et al.  Fibrous astrocytes in Alzheimer's disease and senile dementia of Alzheimer's type , 2004, Acta Neuropathologica.

[61]  T. Morgan,et al.  Increased transcription of the astrocyte gene GFAP during middle-age is attenuated by food restriction: implications for the role of oxidative stress. , 1997, Free radical biology & medicine.

[62]  T. Beach,et al.  Patterns of gliosis in alzheimer's disease and aging cerebrum , 1989, Glia.